Free shipping on all orders over $ 500

GSK3179106

Cat. No. M10933
GSK3179106  Structure
Size Price Availability Quantity
5mg USD 110  USD110 In stock
10mg USD 200  USD200 In stock
50mg USD 780  USD780 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

GSK3179106 is an orally active, selective RET kinase inhibitor for human and rat RET IC50 0.4 nM and 0.2 nM, respectively. GSK3179106 has the potential for use in irritable bowel syndrome (IBS) by reducing post-inflammatory and stress-induced visceral hypersensitivity reactions.

Chemical Information
Molecular Weight 467.41
Formula C22H21F4N3O4
CAS Number 1627856-64-7
Form Solid
Solubility (25°C) DMSO ≥ 60 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Joanne E Kearon, et al. Mol Cell Neurosci. GDNF requires HIF-1α and RET activation for suppression of programmed cell death of enteric neurons by metabolic challenge

[2] John P Russell, et al. J Pharmacol Exp Ther. Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity

[3] John P Russell, et al. Neurogastroenterol Motil. Enteric RET inhibition attenuates gastrointestinal secretion and motility via cholinergic signaling in rat colonic mucosal preparations

[4] Melisa Cooper, et al. Clin Pharmacol Drug Dev. First-in-Human Studies for a Selective RET Tyrosine Kinase Inhibitor, GSK3179106, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers

[5] Hilary Schenck Eidam, et al. ACS Med Chem Lett. Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS

Related RET Products
RET V804M-IN-1 

RET V804M-IN-1 is a wt-RET -selective inhibitors of RETV804M kinase, with an IC50 of 20 nM.

Multi-kinase-IN-5

Multi-kinase-IN-5 is a promising multi-kinase inhibitory agent.

NSC194598

NSC194598 is a p53 DNA-binding inhibitor with IC50 value of 180 nM and 2-40 μM for in vitro and in vivo, respectively.

RET-IN-22

RET-IN-22 is a potent, selective and orally active RET inhibitor with an IC50 of 20.9 nM and 18.3 nM for wild-type RET and RET-V804M, respectively.

RET-IN-23

RET-IN-23 is a potent and orally active RET inhibitor with IC50 values of 1.32, 2.50, 6.54, 1.03, 1.47 nM for RET-WT, RET-CCDC6, RET-V804L, RET-V804M, RET-M918T, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: GSK3179106 supplier, RET, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.